UNSPSC 51312505: Spaglumic acid

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X81L78B3RB. European Medicines Agency schedules Spaglumic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10609MIG. Spaglumic acid generally arises in the molecular formula C11H16N2O8.

The term SPAGLUMIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) Most nations schedule spaglumic acid under HS 29241900 and SITC 51471. As of Q4 2014, SPAGLUMIC ACID remains the US FDA Preferred Term for this commodity. Spaglumic acid bears US NLM identifiers UMLS ID C2348231 and NCI Concept Code C72084. SMILES: CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O.

UNSPSC 51312505 Spaglumic acid is a Commodity code that shows minimal relevant recent activity in state and local procurement. The single posted opportunity under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems, which fall outside the pharmaceutical active-ingredient scope the code nominally describes. The county is seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. Vendors must submit bids electronically, include all shipping and delivery costs in pricing, maintain workers' compensation and commercial general liability coverage, comply with E-Verify requirements, and meet drug-free workplace certification standards. The contract is potentially federally funded through FEMA and carries corresponding compliance obligations under the Clean Air Act and Federal Water Pollution Control Act.

The code shows activity only in Florida at this time, with no additional recent opportunities visible in the source data. The mismatch between the code's nominal pharmaceutical-ingredient classification and the health-department procurement of naloxone and drug-disposal equipment suggests either misclassification in the procurement system or that spaglumic acid itself is not actively solicited by state and local buyers in the current market. Firms evaluating this code should verify whether recent state and local opportunities are consistently filed under this designation or whether procurement offices use alternative codes for similar pharmaceutical and medical-safety procurements.